2026 Poster Presentations
Poster Awards will be awarded Tuesday at 19:10, Wednesday at 17:15, and Thursday at 13:30.
POSTER SESSION A: Tuesday
A001: Overcoming Solid Tumor Heterogeneity with Car T Cells Secreting Anti-EpCAM Bi-Specific T Cell Engagers, Presented by Yvonne Y., A*STAR, Singapore Immunology Network
A002: A New and Differentiated Transgenic Platform for Rapid Generation of Developable Human Therapeutic Antibodies, Presented by Ryan K., AbTherx
A003: A Comprehensive Developability Panel for Accelerating Antibody Development into the Clinic with a Selective and Highly Predictive Set of Assays, Presented by Irina B., Adimab LLC
A004: Predicting Biophysical Properties of Multispecific Antibodies, Presented by Emily R., Adimab LLC
A005: Advancing VHH Therapeutics with Corynex™: Precise Conjugation and Extended Half-Life, Presented by Keita S., Ajinomoto Co., Inc.
A006: NKG2D Ligand Affinity Governs the Antitumor Potency of EGFR-Targeted NK Cell Engagers, Presented by Hyemin L., Ajou University
A007: Engineering Human Hyaluronidase PH20 for Enhanced Thermostability and Catalytic Activity Improves Functional Pharmacokinetics and Therapeutic Efficacy, Presented by Ga-hyun S., Ajou University
A008: Skimune®: A Powerful Human-Centric Platform for the Identification of T Cell Engager Immunotoxicity, Presented by Katie S., Alcyomics Ltd.
A009: Unlocking the Full Potential of Rabbit Monoclonal Antibodies with Cellestive., Presented by John K., Antibody Solutions
A010: Sequence Attribution of a Clinically Thresholded Developability Risk Measure for Antibodies, Presented by Vivek R., Apoha
A011: From In Silico to In Solution: An Integrated Structural Biophysics Workflow for Biologics Developability, Presented by Ketan M., AstraZeneca
A012: High-Throughput Signal Peptide Engineering for Higher Titers and Better Manufacturability Across Protein Modalities, Presented by Yannick D., Avenue Biosciences
A013: Amplifying the Therapeutic Potential of Rabbit-Derived Antibodies by an Advanced, Multi-Parametric Humanization Approach for Single-Step Engineering, Presented by Sander V., AVS Bio
A014: CRB2104: A 2:1 AMHR2/CD3 T Cell Engager Targeting AMHR2-Positive Solid Tumors, Presented by Tinghuan S., Biocytogen
A015: Strategic Engineering of TfR-Mediated Delivery of Oligonucleotides to the Brain and Muscle, Presented by Raeka P., Biogen
A016: Upstream Glycoengineering Approach to Control N-Glycan Profiles of Fc-Mediated ADCC/CDC Biosimilars, Presented by Nick K., Bioworkshops
A017: REM-BAC - A Scalable Path to Precision Engineered Producer Cell Lines, Presented by Sophie H., BOKU - University of Natural Resources and Life Sciences
A018: A Humanized NBSGW Mouse Platform for In Vivo Evaluation of a Humanized Anti-IL-7Ralpha Antibody in Pediatric Leukemia, Presented by Priscila PZS., Boldrini Research Center
A019: Data Generation for Immune Receptor Specificity Models, Presented by Bastian W. & Byeongseon Y. & Yin-Hsi L., Botnar Institute of Immune Engineering (BIIE)
A020: Single-Cell Function Driven Screening and Characterization of Bispecific T Cell Engagers, Presented by Tiago S., Bruker Cellular Analysis
A021: Integrated Biophysical Analysis of Fc–FcR Binding, Affinity, and Avidity in Antibody Therapeutics, Presented by Sven M., Bruker Dynamic Biosensors
A022: Accelerating the Discovery of Therapeutic Antibodies Using High Throughput SPR, Presented by Judicaël P., Carterra, Inc.
A023: Structural Bases of Beta-Chain-Biased Interleukin-2 Variants’ Superagonism: Insights from Enhanced-Sampling Simulations, Presented by Camila C., Center of Molecular Immunology, Cuba
A024: Mapping the Fine Specificity of Anti-SARS-CoV-2 RBD Antibodies Combining Phage Display and Next Generation Sequencing, Presented by Beatriz PM., Center of Molecular Immunology, Cuba
A025: Safety and Efficacy of Bispecific and Multispecific Antibodies, Presented by Sarah V., Creative Biolabs, Inc.
A026: Epitope Mapping Case Studies by Deep Mutational Scanning, Presented by Fabien Q., Deeptope
A027: A Roadmap for Systematic Discovery of Novel Binding Pockets via Macromolecular Crystallography and QMMM, Presented by Jose BN., Diamond Light Source Ltd.
A028: Beyond mAbs: A PBPK Biodistribution Model Spanning scFv, F(ab), Nanobodies, Affibodies and More, Presented by Wilbert D., ESQlabs GmbH
A029: Functional Mapping of the Local TCRab Specificity Landscape, Presented by Luca M., ETH Zurich
A030: OptiMAL®: Mammalian Display for Antibody Discovery, Presented by Pedro C., Fusion Antibodies
A031: A Digital Platform for the Development of Next-Generation Antibody Drug Conjugates (ADCs) and Other Antigen-Targeting Conjugates, Presented by Dario M., Genedata AG
A032: Ensuring Data Quality, Traceability, and Interpretability with Automated Assay Data Workflows, Presented by David S., Genedata AG
A033: Brightfield-Only AI Readouts for T-Cell Killing Assays: Label-Free, Segmentation-Free Hit Calling, Presented by Josefa D., Genentech, Inc.
A034: High-Sensitivity MAPPs for Immunogenicity Risk Assessment of Biotherapeutics, Presented by Wouter D., ImmuneSpec
A035: Structure Guided Engineering of TCR-Mimic Antibodies for Therapeutics, Presented by Owen C., Immunocore Ltd.
A036: Conformationally Diverse Humanised VHH Antibody Library with Favourable Developability, Presented by Peter R., Immunocore Ltd.
A037: Assessment of Individual Antibody Thermal Stability Within a Pool by Phage Display and Next-Generation Sequencing, Presented by Eva L., Institut de Recherche en Cancérologie de Montpellier (IRCM)
A038: Targeting Solid Tumours with MRC2 CAR-T Cells, Presented by Marjan I., Institute of Cancer Research
A039: MRC2 Antibody-Drug Conjugate Targeting Cancer-Associated Fibroblasts, Presented by David V., Institute of Cancer Research
A040: How Specific Are Antibody Therapeutics?: A Systematic Evaluation of Drugs Throughout Preclinical and Clinical Development, Presented by Rachel F., Integral Molecular
A041: Antibodies Against 100+ Impossible Protein Targets: High-Quality mAbs for Previously Intractable GPCRs, Ion Channels and Transporters, Presented by Sharon W., Integral Molecular
A042: Diverse Library Generation Using IDT oPools and Synthetic Biology Custom Solutions, Presented by Jordan K., Integrated DNA Technologies, a Danaher Company
A043: Development of Novel Anti-Malarial Monoclonal Antibodies Against Plasmodium falciparum, Presented by Sadaf P., International Centre for Genetic Engineering & Biotechnology (ICGEB)
A044: From Target to In Vivo: Seamless AI/ML and Wet Lab Integration in T Cell Engager Discovery, Presented by Jürgen K., iOmx Therapeutics AG
A045: De-Risking Biotherapeutics with Human-Relevant NAMs Safety Platform, Presented by Gemma M., IQVIA Laboratories
A047: The Native Edge: KACTUS CD3 VLPs and Nanodiscs for Precision T-Cell Therapy and Discovery, Presented by Anil K., KACTUS
A048: A Versatile Microbial Platform for Rapid GMP Manufacturing of VHH Antibodies, Presented by Quentin N., Kaneka Eurogentec SA
A049: Innovative Antithrombotic and Cardiovascular Disease Therapeutic Strategy Through Development of a Specific Anti-PAR4 Monoclonal Antibody, Presented by Kai-Wen H., Kaohsiung Medical University
A050: In Silico Engineering a Caninized Anti-CD20 Antibody for Safer and More Effective Canine Lymphoma Immunotherapy, Presented by Zih-Yu J., Kaohsiung Medical University
A051: Targeting PEGylated Asparaginase (PEG-ASNase) to B Cell Lymphoma with Bispecific Antibody (CD20 Ab × mPEG scFv) to Enhance Anti-Tumor Activity, Presented by Pin-Jie L., Kaohsiung Medical University
A052: A Membrane-Tethered Chromogenic Enzyme System for Efficiently Monitoring Gene Expression, Presented by Wen-Wei L., Kaohsiung Medical University
A053: Natural Antibody Evolution, Human Expertise, and AI: The MAb-Intelligence Triad for Next-Generation Antibody Discovery, Presented by Casper M., Kling Biotherapeutics
A054: Rapid Isolation and Characterization of High-Affinity Single-Domain Antibodies for Broad-Spectrum Detection of SARS-CoV-2 Variants, Presented by Su Yeon C., Kookmin University
A055: Molecular Basis of CD155-Mediated Immune Regulation Revealed by a Novel Epitope-Specific Human Monoclonal Antibody, Presented by Kyusang H., Kookmin University
A056: Functional Epitope Mapping of Cell Surface Glucose-Regulated Protein 94: A Combinatorial Approach for Therapeutic Targeting, Presented by Sukmook L., Kookmin University
A057: Intrabody Targeting of Insulin Receptor pY1150: A Novel Approach to Modulate Signaling Pathways in Colorectal Cancer Cells, Presented by Ha Gyeong S., Kookmin University
A058: Development of a Novel CD3e-Specific Human Antibody for Selective Modulation of T Cell Activation, Presented by Ha Rim Y., Kookmin University
A059: Advancing Pancreatic Cancer Therapy by Mesothelin-Specific Nanobody Conjugation, Presented by Jinsol C., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
A060: Increasing Brain Half-Life of Antibodies by Additional Binding to Myelin Oligodendrocyte Glycoprotein, a CNS Specific Protein, Presented by Marie-Lynn C., KU Leuven
A061: Driving Patient Impact Through Therapeutic Antibody Discovery, Presented by Sharandip N. & Elisha M. & William M., LifeArc
A062: Accelerating Therapeutic Antibody Discovery with High-Throughput Droplet Microfluidics, Presented by Ellen B., LiveDrop Bio
A063: A Sensitive Aqueous-Phase Cytokine Release Assay for Cytokine Storm Risk Assessment of TGN1412 in Human PBMCs, Presented by Bonita A., Lonza
A064: Demonstration of Lonza’s Intensified Fed-Batch for Multiple Products and Scales, Presented by Anthony B., Lonza
A065: Avidion: High-Throughput Cell Binding Avidity Platform for Screening Cell Engagers, Multispecific Antibodies, and Cell Therapies, Presented by Laura F. & Andrea C., LUMICKS
A066: Towards Validation of Cell Avidity as a Critical Assay for Improving Human Dose–response Prediction and Preclinical Screening of T-Cell Engagers Therapies, Presented by Colin C., Amgen, Inc. & Andrea C., LUMICKS
A067: Engineering Multispecific Antibody Therapeutics for Allergy Prevention, Presented by Yvi S., Mabylon AG
A068: De-Risking TCRm Discovery and Accelerating Specificity Screening with pHLA Libraries, Presented by André F., YUMAB GmbH
A069: From Design to Function: Method Optimization of an Integrated Pipeline for Miniprotein Discovery, Presented by Alessia P., Mario Negri Institute for Pharmacological Research - IRCCS
A070: From scFv Phage Library to Anti-GPA33 Antibody Lead: RSE-05 for Claudin 18.2-Negative Oesophageal Adenocarcinoma, Presented by Radovan K., Masaryk Memorial Cancer Institute
A071: Mapping Antibody Affinity Landscapes from Deep Mutational Scanning, Presented by Stan P., MiLaboratories
A072: Developing a Fully Human CD19 T Cell Engager Using Nona HBICE Platform, Presented by Xiangyu R., Nona Biosciences
A073: Addressing Downstream Bottlenecks in High-Titer Bioprocessing, Presented by Katja G., Novartis Pharma
A074: Optimizing Antigen-Expressing Stable Cell Line Development Using Transposases, Presented by Anett R., Novartis Pharma
A075: Towards a Cross-Format Framework for Early Stage VHH Developability Assessment, Presented by Anette H., Novo Nordisk A/S
A076: Prodrug Antibody for Enhanced Tissue Targeting, Presented by Mie M., Novo Nordisk A/S
A077: pH-Dependent FcRn Binding and Release Assay in a Microplate: A New Method for Screening Fc Interactions of mAbs, Bispecifics and Fc Engineered Antibodies, Presented by Sebastian G., PAIA Biotech GmbH
A078: Kinase Activity Decoupled from Expression: Deep Phosphoproteomic and Metabolic Profiling of KRAS-Mutant Colorectal Cancer Cells, Presented by Kurt H., Panome Bio
A079: Same Assay, Stronger Signal: Ultra Beacons – Nanoparticle Signal Amplification for Ultra-Bright Antibodies in High-Sensitivity Assays, Presented by Richard K., Plectonic Logibody GmbH
A080: Seeing the Whole Story: Richer Molecular Information for Faster Antibody Development, Presented by Micol D., Portal Biotech Ltd.
A081: The Pfenex Platform for Preclinical VHH-ADC Development, Presented by Jeff A., Primrose Bio
A082: Ankyrons® - Next Generation Target Binding and Detection, Presented by William T., ProImmune, Inc.
A083: Progressive Deconvolution Provides Robust Feature Detection and Quantitation for Large Mass Intact MS Analyses, Presented by David P., Protein Metrics by Dotmatics
A084: Antibody and Therapeutics Discovery: Validating Multi-Dataset Enrichment Analysis Against a Published Phage Display Campaign, Presented by Monica W., Protein Metrics by Dotmatics
A085: Characterization of Vector Integration of Proteonic 2G UNic® Transposon Technology, Presented by Annemarie D., ProteoNic
A086: De-Risking the TCE Development Journey, Presented by Andrea B., RoukenBio
A087: IndEx-2: An Inducible Cell Line Platform to Evaluate the Impact of Target Antigen Density on Immunotherapeutics, Presented by Lewis C., RoukenBio
A088: Xdrop®: High-Throughput Screening in Antibody Discovery, Presented by Trine Ø., Samplix ApS
A089: Novel TCR Discovery Platform Driving Bispecific T Cell Engagers Against Highly Abundant Solid Tumour Targets, Presented by Maria B., T-Cypher Bio
A090: Structure-Based Prioritization of Flexible Linkers for Optimization of PROTAC Potency, Presented by Danna D., Technische Universität Darmstadt
A091: Isolation of Disulphide-Rich Bovine Ultra long CDRH3 Domains Using Fc-Based Yeast Surface Display, Presented by Yifei L., Technische Universität Darmstadt
A092: Distinct Contributions of Non-Canonical Disulfide Bonds to Stability and Conformational Dynamics of VHHs, Presented by Jing L., Technische Universität Darmstadt
A093: Targeted Therapeutics: Antibody functionalized LNPs for the Treatment of Ovarian Cancer, Presented by Anna W., Technische Universität Darmstadt
A094: Redefining Clarification: Chromatographic Approaches for High-Density Bioprocessing, Presented by Jack C., Thermo Fisher Scientific
A095: pH-Dependent Antibody Screening, Presented by Chuanting T., Tsingke Biotech
A096: Antibody Discovery from Immune VHH Library Using Yeast Surface Display, Presented by Lynette T., Twist Bioscience
A097: Enhancing Antibody Optimisation with Yeast Display, NGS, and Protein Language Models, Presented by Irene F., UCB Biopharma
A098: Elucidating the Anti-Leukemic Mechanism of a Novel Anti-IL7Ra Antibody in Pediatric Leukemia, Presented by João F., Universidade Estadual de Campinas (UNICAMP)
A099: PeptiForge: Rapid, High-Quality Discovery of Peptide and Protein Binders, Presented by Bryan D., University of Chicago
A100: Modulation of Cellular Immunity by the Potent Natural Antioxidant Astaxanthin via Protein Interactions, Presented by Alvar MU., University of Graz
A101: AI-Assisted Development of a TCR-Like T Cells Engager Targeting MAGE-A4 Against Melanoma, Presented by Yang L., Canton Biologics
A102: Germline-Guided Redesign of Therapeutic Antibodies to Co-Optimize Developability and Affinity, Presented by Eva H., University of Michigan
A103: Next-Generation Phage Display for the Identification of Novel Glycosaminoglycan Antibodies, Presented by Kieran P., University of Nottingham
A104: Conditionally Active T-Cell Engagers for Tumor Therapy, Presented by Ann-Kathrin L., University of Stuttgart
A105: Novel Antibodies Targeting the Human Cytomegalovirus (HCMV) Immune Evasins gp34 and gp68, Presented by Dennis M., University of Stuttgart
A106: Novel Antibodies Targeting CCR9 for Cancer and Inflammatory Diseases, Presented by Helena N., University of Stuttgart
A107: Fc Heterodimerization via Asymmetric ß-Strand Redistribution, Presented by Arkaitz CA., University of the Basque Country
A108: Development of Antibody Fragments as Medical Countermeasures to Reverse Drug-Induced Toxicity, Presented by Brooke H., University of Washington
A109: Affinity-Bound Antibody LNPs Enable Targeted Delivery of mRNA to T Cells In Vivo, Presented by Alexandros K., Uppsala University
A110: Adapter Proteins Enable Polytypic Delivery and Neutralizing Antisera Against Alphaviruses in Mice, Presented by Gustavo A., Vanderbilt University
A111: A Conditionally Active T Cell Engager Platform Enabled by Split-CD3 Engineering, Presented by Jorge LR., VERAXA Biotech GmbH
A112: Multipurpose Cell Avidity Measurements Using the CellVysion SPR Imaging Platform, Presented by Anouk M., Vysens B.V.
A113: Multi-Specific Engagement Studies with World’s First Cell Avidity SPR Imaging Platform: The CellVysion, Presented by Anouk M. & Richard S., Vysens B.V.
A114: MOA-Guided In Vivo Pharmacology Characterization of T Cell Engagers Using Complementary NHP and Murine Models to Support Translational Assessment, Presented by Lorenz F., WuXi Biologics
A115: Seamless Integration of Antibody Purification and ADC Conjugation: An Innovative Approach for Efficient Manufacturing, Presented by Xudong D., WuXi XDC
A116: Accelerating Next-Generation Targeted Conjugates Through Integrated Discovery, Presented by Jiawei L., WuXi XDC
A117: Integrated Analytical Platform Advancing Emerging Bioconjugate Development, Presented by Nan Z., WuXi XDC
A118: Accelerating Antibody Discovery with Full-Length IgG Display on CHO Cells, Presented by Thomas S., YUMAB GmbH
A119: Validation of a Surface Plasmon Resonance Assay for Assessing GLP-1 Analog Binding Activity, Presented by Ziva R., Labena doo
A120: Bridging AI-Driven Protein Design and Wet-Lab Validation Through Cell-Free Expression, Presented by Linlin Z., Sino Biological Europe GmbH
A121: AI-Engineered NovoBody™-Based Probe for “High Capacity, Low Drift” BLI Analysis of His-Tagged Proteins, Presented by Benjamin O., Gator Bio
A122: Directed Design of Developable Human IgGs — From Soluble Targets to GPCR Agonism, Presented by Robin A., Pythia Labs
A123: Multiple Phagemids Within Single Bacterial Colonies During Construction and Bio-Panning of Single-Domain (VH and VHH) Phage Display Libraries: A Retransformation Strategy for Reliable Clone Screening, Presented by Kyeong Eun K., Seoul National University
A124: Template-Choice Bias in Deep Sequencing of Antibody Phage Display Libraries, Presented by Hyunji Y., Seoul National University
POSTER SESSION B: Wednesday
B001: A Screening Platform to Find a Cure for Ebola, Presented by Vera B., 2bind GmbH
B002: Opti-mAb®: A Novel scFv Format for Improved Therapies, Presented by Ionut D., AAX Biotech AB
B003: Generative Design of pH-Sensing Antibodies for T Cell Engagers: Mesothelin and CD3e, Presented by Jean-Philippe B., Ability Biotherapeutics
B004: Comprehensive Analysis of Monoclonal Antibodies and Antibody-Drug Conjugates Across Multiple Analytical Levels, Presented by Marco R., Agilent Technologies
B005: Expanding the Potential of Antibody Conjugates: AJICAP® Technology for Versatile DAR Control and Novel Modality Applications, Presented by Yusaku N., Ajinomoto Bio-Pharma Services
B006: A Next-Generation Bispecific ADC Platform for Enhanced Solid Tumour Therapy and the Treatment of Drug-Resistant Cancers, Presented by Jennifer T., Almac Discovery Ltd.
B007: From Structure to Solution: Accelerating Biologics Discovery with ALPX, Presented by Oliver DA., ALPX
B008: ARC-401, a Triple Payload First-in-Class ADC Against Nectin-4 Designed to Overcome Cancer Resistance and Tumor Heterogeneity, Shows Broad Anti-Tumor Activity and High Tolerability in Relevant Animal Models, Presented by Marcos GG., Araris Biotech AG
B009: Automated Large-Scale Biologics Expression Platform, Presented by Jenny K., AstraZeneca
B010: Next-Generation Antibody–Drug Conjugates: High Drug Loading and Multiple Payloads, Presented by Victor LA., AstraZeneca
B011: Integrating Structural Biology and Biophysical Characterisation to Accelerate Drug Discovery, Presented by Edmond W., AstraZeneca
B012: Boosting Diversity-Focused Lead Antibody Generation by In Silico-Guided Rare Hit Magnification and Epitope-Driven Affinity Finetuning, Presented by Ilse R., AVS Bio
B013: BCG015: A First-in-Class Antibody-Drug Conjugate Targeting TM4SF5 for the Treatment of Hepatocellular Carcinoma, Presented by Di F., Biocytogen
B014: RenSuper Workstation™: An AI-Powered, Closed-Loop In Vivo Discovery and Automation Engine for High-Efficiency Therapeutic Antibody Generation Infrastructure, Presented by Di F., Biocytogen
B015: Engineering pH-Responsive Antibodies Through Framework-Guided Design: A Universal Platform for Antibody Recycling and Enhanced Biologic Performance, Presented by Christoffer S., BioInnovation Institute Foundation
B016: AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution, Presented by Lei S., Biointron
B017: Accelerating Anti-Biotherapeutic Tool Antibody Development with Bio-Rad's Pioneer Select Platform, Presented by Katharina R., Bio-Rad Laboratories
B018: Generation of Fc-Mutation Specific Antibodies Using Phage Display, Presented by Yvonne S., Bio-Rad Laboratories
B019: Understanding the Influence of Protein Surface Mutations on Expressibility: Variant Library Analysis with Explainable AI, Presented by Fiona P., BOKU - University of Natural Resources and Life Sciences
B020: Strategies for Scalable and Sensitive Determination of High Affinity and Slow Dissociating Binding Interaction Kinetics in Antibody Discovery, Presented by Judicaël P., Carterra, Inc.
B021: Engineering Orthogonal CH3 Interfaces for Enhanced Bispecific Antibody Production, Presented by Margot G., CEA - French Alternative Energies and Atomic Energy Commission
B022: Identification of the Molecular Interface Between the Envelope and Capsid Proteins in Hepatitis B Virus, Presented by Carolanne V., Centre National de la Recherche Scientifique (CNRS)
B023: Pharmacophore-Guided Virtual Screening of Antibody Formats, Presented by Andrew H., Chemical Computing Group
B024: Reprogramming the Genetic Code for the Recombinant Production of Next-Gen Biotherapeutics, Presented by Peter S., Constructive Bio
B025: A Robust and Comprehensive Development Framework for Antibody-Oligonucleotide Conjugates (AOCs), Presented by Sarah M., Creative Biolabs, Inc.
B026: Antibody Optimization Case Studies by Deep Mutational Scanning, Presented by Charlotte P., Deeptope
B027: RedQueen: Digital Directed Evolution of Antibody Paratopes for Challenging GPCR Targets, Presented by Clarissa E., Discovery Evolution
B028: Functional Profiling of TME-Dependent Immunotherapies in Live Human Tumour Fragments, Presented by Ralph G., Elephas Biosciences
B029: IgE: Ultra-High Efficacy for Ultra-Low Antigen Tumours, Presented by Nikhil F., Sarah G & Veronica I., Epsilogen Ltd.
B030: Engineering the Drosophila S2 Platform: From Complex Protein Expression to Phase III Clinical Manufacturing, Presented by Max S., ExpreS2ion Biotechnologies
B031: Mastering the Molecule: Bioconjugation and In-Depth Characterization Strategies, Presented by Adriana G., FairJourney Biologics
B032: Driving Antibody Optimization with Broad-Space and Structure Guided Platforms: Tumbler™ and Targeted Engineering, Presented by Bruno L., FairJourney Biologics
B033: Functional Tailoring: A Sensitive Reporter Cell Line for Screening of Agonistic Anti-OX40 Antibodies from Single B-Cell Campaigns, Presented by Mário S., FairJourney Biologics
B034: In-Depth Characterization of Antibody-Drug Conjugates by Subunit-Level Mass Spectrometry, Presented by James D., Genedata AG
B035: Performance Characterization of a Recombinant Protease Platform for Bottom-Up Proteomics, Presented by Jantje M., Genovis AB
B036: Pan-Immunoglobulin Capture and Native-State Antigen Release Using AlligBAITOR™, Presented by Philip W., Genovis AB
B037: 4-Day Sequence-to-Data: Accelerating AI-Driven Protein Discovery via Integrated Cell-Free Workflow, Presented by Lucas S., GenScript
B038: Production and Purification of Virus-Like-Particles in HighFive Cells for Various Applications, Presented by Rena H., Helmholtz Centre for Infection Research
B039: Cognate Chain Expression Imbalance: A Key Driver of Bispecific Antibody Mispairing in CHO Cells, Presented by Jose E., iBET - Instituto de Biologia Experimental e Tecnológica
B040: Optimization and Biophysical Characterization of Site-Specific PEGylation of Recombinant FabC11 for Shiga Toxin 2 Neutralization, Presented by Ariela B., Instituto Butantan
B041: Engineering GPRC5D Multispecific Antibodies: Parallel Engineering to Optimize Affinity, Developability, Species Reactivity, and IP, Presented by Ross C., Integral Molecular
B042: A Comparison of Preclinical Models for PK Allometric Scaling of Antibodies, Presented by Adriano F., Jackson Laboratory
B043: A Humanized FcRn x Albumin Model to Assess HSA-Fused Therapeutic Candidates and FcRn Antagonists, Presented by Philip G., Jackson Laboratory
B044: Unlocking the Complete KLK Family: Active-Form, Multi-Species and Ultra-Pure, Presented by Jia C., KACTUS
B045: Accelerating Cell Line Development Through Robust Selection Strategies And Automation, Presented by Morgane B., KBI Biopharma
B046: Development of a Novel Polypeptide-Based IDP Tag for Long-Acting Biologics, Presented by Saehae C., KBIOHealth - OSONG Medical Innovation Foundation
B047: Development of an AI-Powered Antibody and Protein Design Platform, Presented by Hyeonjeong Y., KBIOHealth - OSONG Medical Innovation Foundation
B048: Toward True Sub-nM Affinity Readouts of Antibodies in SPR with K-One Surface Chemistry, Presented by Claude N., Kimialys
B049: RMCE-Based Genome-Wide CRISPR Screening to Enhance CHO Cell Fitness Under Ammonia Stress and Hypothermia, Presented by Seokchan K., Korea Advanced Institute of Science & Technology (KAIST)
B050: Development of a Macrophage Mediated Payload Delivery System for Precise Solid Tumors Therapy, Presented by Hyeseon L., Korea Advanced Institute of Science & Technology (KAIST)
B051: Engineering Yeast Metabolism and Heterologous Gene Expression with Rap1 for Enhanced Triterpenoid Saponin Production, Presented by Thi Thuy N., Korea Advanced Institute of Science & Technology (KAIST)
B052: Engineering a Soluble Dimeric Protein Platform in Escherichia coli, Presented by Young Su K., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
B053: Targeting the TSLPR Heterodimer Interface: AI-Driven Design of Nanobinders to Suppress Type 2 Inflammatory Signaling, Presented by Jaerin K., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
B054: Retrofit Platform: Engineering Next-Generation Antibodies Against the Root Causes of Immune Resistance, Presented by Catherine H., KU Leuven
B055: Analytical Similarity Assessment of a Monoclonal Antibody Biosimilar Through Orthogonal Structural and Functional Characterization, Presented by Rocío C., Leanbio
B056: GlycoConnect® Dual-Payload ADCs with SYN-duo® CA, Which Combines a Camptothecin and an Auristatin Payload, Demonstrate Enhanced Anti-Tumor Efficacy Compared to Respective Mono-Payload ADCs, Presented by Leonie K., Lonza
B057: GS Ori-Go®: Next-Generation CHO Expression Vectors for Enhanced Productivity, Stability and Speed, Presented by Peter O., Lonza
B058: Affinity Optimization of Anti-TfR1 VHH Blood-Brain Barrier Crossers for CNS Delivery Applications, Presented by Anette S., Lonza
B059: From Design to Function: An Integrated Platform for Miniprotein Discovery Targeting Gelsolin, Presented by Marten B., Mario Negri Institute for Pharmacological Research - IRCCS
B060: Connectase: Next Generation Bioconjugation, Presented by Adrian F., Max Planck Institute for Biology
B061: Connectase: Antibody Conjugation Without Compromise, Presented by Janes K., Max Planck Institute for Biology
B062: Sequence-Only Antibody Generation Yields a pH-Sensitive, Cross-Reactive Mesothelin Campaign Lead, Presented by Lucas N., McGill University
B063: Structural Characterization of Novel VHH-Based Binders Targeting the C5 Complement Protein, Presented by Ulrich G., Merck Healthcare KGaA
B064: A Fast and Integrated Workflow for the Discovery of Highly Internalized Anti-HER2 ADCs, Presented by Marie H., MImAbs SAS
B065: Designing Coil-Functionalized Antibodies with Preserved Manufacturability for the Generation of Antibody-Drug Conjugates, Presented by Ilona M., National Research Council Canada & Polytechnique Montreal
B066: Where Does It Go? A Reporter Dye System to Investigate ADC Trafficking and Release Kinetics In Vitro and In Vivo, Presented by Lukas K., NBE-Therapeutics AG
B067: AI-Based Optimisation of Immunogenicity Profile for Biologics, Presented by Giulia P., NEC Bio Therapeutics GmbH
B068: Bridging the Translational Gap: In Vitro Platforms for Assessing Therapeutic Depletion Mechanisms, Presented by Karina D., Nexus BioQuest
B069: Fully Human HACb Antibody Discovery Enhanced by Hu-mAtrIx AI-Integrated Platform, Presented by Andre S., Nona Biosciences
B070: AI-Guided Optimization for Therapeutic Proteins: Computational Variant Generation, Prioritization and Experimental Validation Across Developability, Affinity, and Immunogenicity-Risk Objectives, Presented by Dieter S., nuantic AG
B071: Predicting PAIA Developability Readouts of Bispecific Antibodies From Monospecific Parentals, Presented by Anna J., PAIA Biotech GmbH
B072: An Integrated Capillary Electrophoresis Strategy for Monoclonal Antibody Characterisation Across the Product Lifecycle, Presented by John A., Pharmaron
B073: Utilization of Naïve VHH Phage Display Library and Integrated Antibody Engineering Platform to Generate Antibody Leads for CAR-T Therapy, Presented by Nicolas S., ProBio
B074: Light as a Novel Process Lever: High Productivity CHO Manufacturing With Applications in Monoclonal Antibodies and Beyond, Presented by Alexander N., Prolific Machines
B075: Bioluminescent Assays for Antibody Drug Conjugate Development: Internalization and Bystander Killing Functions, Presented by Steven E., Promega Corporation
B076: Automated, High-Throughput Screening of Complex Biologics, Presented by David L., Protein Metrics by Dotmatics
B077: Boosting CHO Cell Productivity with 2G UNic Vector Technology and Transposon Innovation, Presented by Bart E., ProteoNic
B078: Mass Photometry Reveals Bevacizumab:VEGF Stoichiometry and FcγRIIa Engagement, with Heparin-Dependent Complex Modulation, Presented by Nina JJ., Refeyn Ltd.
B079: Rapid Screening Disulfide Scrambling Analysis of IgG1 by LC-MS, Presented by Marcin W., Rezon Bio
B080: De-Risking Protein Biologics Through Comprehensive Developability Assessment, Presented by Carolin B., RIC Biologics
B081: High-Performance Antigen Affinity Chromatography of Monoclonal Antibodies in One- And Multidimensional Configurations, Presented by Thomas M., RIC Biologics
B082: Evaluation of Disulfide Bond Scrambling in Monoclonal Antibodies by Peptide Mapping in Non-Reducing Conditions, Presented by Mabelle M., RIC Biologics
B083: An Orthogonal Cis-Targeting Platform for Delivery of Attenuated Cytokines to Chimeric Antigen Receptor T Cells, Presented by Julia F., Roche Glycart AG
B084: An Integrated Human Assay Cascade for ADC Evaluation: From Target Engagement to Complex Tumour Microenvironment Activity, Presented by Ian G., RoukenBio
B085: Beyond FcRn Binding: Functional and Kinetic Profiling of Fc-Engineered Antibody Recycling, Presented by Patricia RR., RoukenBio
B086: Defeating Albumin's Limits Using Novel pH-Dependent FcRn-Binding NANOBODY® Clones: Dual FcRn-Albumin Binding Redefines NANOBODY® Half-Life, Presented by Judith V., Sanofi
B087: Next Generation Bioproduction: A Novel Engineered CHO Host for Optimized Performance in Fed-Batch and Perfusion, Presented by Jimit S., Sartorius Stedim Cellca GmbH
B088: Accurate In Silico Prediction of pH-Dependent Antibody Binding Affinities Using Robust Physics-Based Methods, Presented by Dan C., Schrödinger, Inc.
B089: Enhancing Protein Purity Analysis Using CE-SDS with Native Fluorescence Detection, Presented by Stephen L., SCIEX
B090: Sustained Uric Acid-Lowering Activity of CanopyPEG-Uricase Compared with Conventional mPEG-Uricase Following Repeated Administration, Presented by Sang-Uk N., SunBio, Inc.
B091: TLT-001: Preclinical Development of a CDH17-Targeted Antibody-Drug Conjugate and Validation of Target-Specific Anticancer Efficacy, Presented by Young Sun O., Target Link Therapeutics
B092: Specificity-Driven Protein Binder Design with Odin-Multi, Presented by Valentas B., Technical University of Denmark
B093: Development of a Recombinant, Epitope-Diverse Human IgG Fc Detection Platform, Presented by Adrian B., Technische Universität Darmstadt
B094: Trispecific Antibody Drug Conjuagtes for Cancer Therapy, Presented by Martina B., Technische Universität Darmstadt
B095: Antibody-Degrader-Conjugates: Overcoming Biochemical and Biophysical Hurdles, Presented by Alessandro E., Technische Universität Darmstadt
B096: Engineering a Tumor-Targeted Attenuated IL-12 Immunocytokine with ADCC-Dependent Granzyme B–Mediated Activation and pH-Driven Developability Optimization, Presented by Felix G., Technische Universität Darmstadt
B097: Engineering Magrolimab for Conditional and Tumor-Selective CD47 Targeting, Presented by Armin H., Technische Universität Darmstadt
B098: A Selectively Activated D-aa Specific Protease to Enable Selective Drug Release in the TME, Presented by Viktoria H., Technische Universität Darmstadt
B099: Rigidifying Bispecific sdAbs: Tuning IL-21 Mimetic Agonism by Paratope Geometry, Presented by Britta L., Technische Universität Darmstadt
B100: Enhancing Viral Vector Purification Through Binder Design: Integrating In Silico and Experimental Approaches, Presented by Alice M., Teesside University, National Horizons Centre
B101: Express Screening Antibodies: SPR Data from Cell Free IgG. Expression as Few as 5 Business Days, Presented by Hoa G., Twist Bioscience
B102: Accelerating Multispecific Antibody Discovery and Development. Robust, Easy to Access, Industry-Leading Bispecific Platform, Presented by Emilie M., Twist Bioscience
B103: 2D-LC for Rapid Functional and Structural Characterization of Reversible Antibody Dimers, Presented by Larissa L., Ulm University
B104: Combining Phage and Yeast Display to Engineer Analytical Antibodies for Sesame Allergen Detection, Presented by Santiago R., Universidad Complutense de Madrid
B105: Targeting IL7Ra with a Humanized Monoclonal Antibody: Therapeutic Potential in B- and T-Acute Lymphoblastic Leukemia, Presented by Fernando M., Universidade Estadual de Campinas (UNICAMP)
B106: A Humanized Monoclonal Antibody Targeting IL-7Ra Shows Selective Binding and Preclinical Antileukemic Activity, Presented by Joey R., Universidade Estadual de Campinas (UNICAMP)
B107: Development of a Stable Cell Line Producing Anti-IL7R Antibodies by Site-Specific Integration, Presented by Manuela V., Universidade Estadual de Campinas (UNICAMP)
B108: ONCOMAB: A Platform for the Expression, Purification and Engineering of Patient-Derived Antibodies for Cancer Immunotherapy in Brazil, Presented by Solon AR., Universidade Federal do Rio Grande do Sul
B109: Advancing Recombinant IgA Antibody Production, Presented by Camila D., Universidade Federal do Rio Grande do Sul
B110: Directing Generative AI Through Phage Display Screening: Evaluating a Hybrid Sequence-Structure Pipeline for GPCR Peptide Discovery, Presented by Ajay P., University College Dublin
B111: Interfering with α-Synuclein/Glycosaminoglycan Axis for Drug Development, Presented by Paula P., University of Graz
B112: Rabbit-Derived VL Single-Domain Antibodies and In Vivo Phage Display Selection for Next-Generation ADC Development, Presented by Frederico AS., University of Lisbon
B113: Engineering HER2-Targeted Immunotoxins with PE38 and Diphtheria Toxin Across Human and Feline Mammary Cancer, Presented by Magda F., University of Lisbon
B114: Precipitate or Stabilise? How pH and Charge Control ATP and Tripolyphosphate Effects on Proteins, Presented by Deva K., University of Manchester
B115: A New Strategy of IgG Engineering to Improve Tumor Penetrability, Presented by Ainhoa G., University of the Basque Country
B116: Cell-Free Production and Evaluation of Antimicrobial Peptides, Presented by Anna D., University of Victoria
B117: An Avidity-Driven, Bispecific ADC with Superior Tumor Selectivity Enables PDB Payloads to Treat Solid Tumors, Presented by Sebastian L., VERAXA Biotech GmbH
B118: Mechanism-Guided In Vitro Characterization of Antibody-Drug Conjugates for Candidate Optimization and Differentiation, Presented by Wanchen L., WuXi Biologics
B119: MoHuTS: Multi-Objective Tree Search for Antibody Humanization, Presented by Kiichi Y., Yokohama City University
B120: From High-Quality mAb Discovery to Multispecific Therapeutics: Discovered. Designed. Delivered., Presented by Belinda W., Invenra, Inc. and WB Consulting
B121: Enabling Rapid Bispecific Antibody Discovery with Invenra’s B-Body Platform, Presented by Belinda W., Invenra, Inc. and WB Consulting
B122: Navigating the CDR Landscape: High-Throughput Single-Molecule Mapping Yields a Long-Acting GIPR Antagonist for Obesity Maintenance Therapy and GLP-1 Synergy, Presented by Jihye J., PROTEINA Co., Ltd.
POSTER SESSION C: Thursday
C001: Direct Proteomic Discovery of Circulating Antibodies Yields Potent Neutralizers Overlooked by BCR Sequencing, Presented by Maurits D., Abvion Biologics B.V.
C002: Integrated Strategies for Producing Functional Recombinant Proteins to Advance Autoimmune Disease Therapeutics, Presented by Mourad F., ACROBiosystems
C003: Stable Co-Formulation of Cagrilintide and Semaglutide Enabled by the BioChaperone® Technology for Multi-Dose Pen Injectors, Presented by Guillaume L., Adocia
C004: Complementary Methodologies for Analysis of NIST mAb Impurities Using Agilent LC and CE Systems, Presented by Christian W., Agilent Technologies
C005: De Novo Design of Mini-Proteins as Specific Binders to PACAP-38, a Key Mediator of Migraine, Presented by Hiroki Y., Ajinomoto Co., Inc. and Imperial College London
C006: Targeting Polymeric Gene Delivery Platform for T Cell Reprogramming, Presented by Justine H., Alaya.bio
C007: High Velocity Approach to Antibody Discovery and Optimization Using AI-Enabled and ML-Powered In Silico Workflows Combined with High-Throughput Expression and Testing, Presented by Mason M., Alloy Therapeutics
C008: A Format-Independent, Coalescence-Based Physical Readout for Developability, Formulation and Predictive Models, Presented by Jack H., Apoha
C009: Engineering Precision with CHO Edge: A Framework for Producing Complex Multispecific and Difficult-to-Express Proteins, Presented by Thibault L., Asimov
C010: A Next-Generation Rabbit B Cell Antibody Platform, Presented by Aaron F., AstraZeneca
C011: Diversity that Delivers: Structurally Designed Libraries Powering Peptide Binder Discovery, Presented by Qiuran P., AstraZeneca
C012: Unlocking Precision: The Versatility of the Athebody Platform for Targeted Therapeutics, Presented by Johannes U., Athebio AG
C013: Novel Bispecific Approach to Eliminate Light Chain Mispairing, Presented by Mario P., ATUM
C014: An Integrated Workflow for Accelerated VHH Identification and Characterization with High-Throughput Functional Assays: A Comprehensive Case Study on CDK2/CycE1 Complex, Presented by Tommaso T., Axxam S.p.A.
C015: SV-AUC Characterization of Peptides: A Case Study with Semaglutide, Presented by Lutz E., Beckman Coulter
C016: Automated Cell Handling and Lipofection-Based Transient Transfection Design of Experiments (DOE) on the New Biomek i3 Benchtop Liquid Handler, Presented by Friederike J., Beckman Coulter
C017: Rapid, High-Throughput IgG Quantification in Crude Cell Culture Samples, Presented by Uwe K., Beckman Coulter
C018: Peptide-Centric Interface Topology Distinguishes Selective MAGE-A4 Directed TCR-Mimic Antibodies, Presented by Christoph R., BioCopy AG
C019: ValidaTe®-Guided Discovery of a Potential Best-in-Class MAGE-A4/HLA-A02:01 (GVY) Directed TCRm-Based T-Cell Engager with Superior Specificity, Presented by Simon S., BioCopy AG
C020: Validate®: Proteome-Wide Off-Target De-Risking of HLA-A02:01 MAGE-A4 TCR-Mimic Antibodies, Presented by Oliver S., BioCopy AG
C021: Novel Blood-Brain Barrier Penetrating Heavy Chain-Only Antibodies Targeting CD98, Presented by Benny Y., Biocytogen
C022: Comprehensive Multi-Omics and Functional Profiling Gives Insights into Mechanisms Driving Resistance to Antibody-Drug Conjugates, Presented by Tobias L., Biofidus AG
C023: 3D BioSPHEER™ Models for Functional Evaluation of Cancer Therapies, Presented by Natasha HM., Bioneer
C024: Bio1Run Methodology: Accelerating Production Mode Decision-Making, Presented by Christian M., Bioneer
C025: Rapid Lead Generation with the Pioneer Antibody Discovery Platform, Presented by Christian F., Bio-Rad Laboratories
C026: Viscosity Prediction of High-Concentration Antibody Solutions from All-Atom MD Simulations, Presented by Michaela B., Boehringer Ingelheim Pharma GmbH & Co. KG
C027: End-to-End Automation Enables 10-Fold Expansion of Early-Phase Formulation Design Space Exploration, Presented by Frank H., Boehringer Ingelheim Pharma GmbH & Co. KG
C028: CM101: A Cell-Penetrating VHH for Intracellular Immune Checkpoint Inhibition, Presented by Miriam AL., Cellmover AS
C029: Structure-Based Charge Calculations for Predicting Properties and Profiling Antibody Therapeutics, Presented by Purvi G., Chemical Computing Group
C030: FT-IR-Based Multi-Attribute Approach for Quantification of APIs and Excipients in Coformulations, Presented by Maximilian R., CLADE GmbH
C031: Active-Learning Design of Peptide Binders to Bacterial Endotoxin LPS, Scored with Umbrella Sampling, Presented by Jyler M., Concordia University
C032: To Platform or Not to Platform: Using the ReFOLD Assay and Formulation Sensitivity to Guide Early Development, Presented by Kristian L., Coriolis Pharma Research GmbH
C033: PlateX MP™: Automated Full-Length Membrane Protein Preparation for Ligand Screening and Hit-to-Target Identification, Presented by Philipp H., Cube Biotech GmbH
C034: Computational Light Chain Design for VH-Only Library Screening, Presented by Emily B., DaltonTx
C035: The Application of Nanodisc Technology Platform to Develop Therapeutic mAbs for Multi-Pass Transmembrane Protein Targets, Presented by Donghui M., DIMA Biotechnology
C036: Mapping GPCR States to Guide State-Selective Antibody Design, Presented by Georg R., Discovery Evolution
C037: Computational Design of Functional Nanobodies for G-Protein Coupled Receptors, Presented by Shuhao Z., EPFL - Swiss Federal Technology Institute of Lausanne
C038: From Transient to Trustworthy: eviCHO Delivers Biosimilars Comparable to Stable Cell Lines and Originators, Presented by Fruhar M., evitria AG
C039: Overcoming scFv Instability in Complex Multispecific Formats with Opti-mAb®, Presented by Julia P., evitria AG
C040: Enabling Bispecific Antibody Development Through Integrated Discovery and Humanization, Presented by Carolina T., FairJourney Biologics
C041: Applying FIDA for In-Solution Binding Kinetics, Presented by Kritika R., Fidabio
C042: A Platform for Generating Rabbit Monoclonal Antibodies Against Membrane Proteins Using Antigen-Loaded Extracellular Vesicles, Presented by Takahide M., FUJIFILM Wako Pure Chemical Corporation
C043: An Automated High Throughput Engineering Platform for AI-Supported Developability Predictions, Presented by James M., Genedata AG
C044: Smart Analysis of Experimental Context and Accelerated Biologics Lead Optimization Through AI-Guided Developability Workflows in Hit Profiler, Presented by Stephan S., Genedata AG
C045: Leveraging High-Throughput Platforms for the Discovery of Bispecific Antibodies, Presented by Andreas M., GENEWIZ from Azenta Life Sciences
C046: Accelerating Antibody Discovery: High-Throughput Solutions for Producing Antibodies at Scale, Presented by Prassanna R., GENEWIZ from Azenta Life Sciences
C047: Accelerate the Design-to-Data: Scalable Purification Automation for AI-Driven Biologics Discovery, Presented by Luciana RM., GenScript
C048: Discovery of Functional Antibodies Against Challenging Membrane Protein Targets, Presented by Siret T., Icosagen Cell Factory OÜ
C049: Advancing Antibody Developability Assessment: Integrating Gen3 Discovery with Orthogonal Polyreactivity Screening Approaches, Presented by Luis R., IQVIA Laboratories
C050: Multi-Task Learning for Predicting Peptide Developability Properties, Presented by Rebecca B., Imperial College London
C051: Pep_Dez: An AI-Guided Active Learning Framework for the Rapid Design of De Novo Peptide Disruptors of Protein-Protein Interactions, Presented by Bharath P., Indian Institute of Technology, Madras
C052: Universal Landing Pad Technology for Highly Efficient Cell Line Engineering, Presented by Tobias M., InSCREENeX GmbH
C053: Single Copy CHO Landing Pad for Probing Target Libraries, Presented by Kristina N., InSCREENeX GmbH
C054: Robust Polysorbate Analysis of Protein-Rich Biopharmaceuticals Using EDTA/Ethanol Precipitation and Scavenger Column Cleanup, Presented by Vincentius H., Johnson & Johnson Innovative Medicine
C055: Combination of Lenalidomide and Dexamethasone with Pro-Anti-PD-1 Antibodies for Enhanced Safety and Efficacy in Multiple Myeloma Therapy, Presented by Chia-Yi L., Kaohsiung Medical University
C056: Preserved Antiviral Efficacy of Approved COVID-19 Therapeutics Against Emerging SARS-CoV-2 Omicron Subvariants, Presented by Junhyung C., Korea National Institute of Health
C057: Discovery and Characterization of a Dual-Acting Antiviral Compound Targeting SARS-CoV-2 3CLpro and Host Cathepsin L, Presented by Kyung-Chang K., Korea National Institute of Health
C058: Impurity Profile-Guided Purification Strategy for Knobs-into-Holes Bispecific Antibodies, Presented by Seo-Yeong H., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
C059: CRISPR/Cas12a2 Enables Ultra-Sensitive Amplification-Free RNA Detection, Presented by Ju-Eun K., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
C060: Enhancement of Collateral Activity Using Engineered CRISPR-Cas12j and Tailored Reporters, Presented by Younghoon L., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
C061: De Novo Design of Hyperstable PD-L1 Nanobinders, Presented by Kwang-Hyun P., Korea Research Institute of Bioscience and Biotechnology (KRIBB)
C062: Engineering Obligatory TIM3xVISTAxCSF1R Tri-Specific Antibody to Unlock TAM Anti-Tumoral Function, Presented by Jenny S., KU Leuven
C063: Integrated Membrane Protein Production and Structural Biology for Biologics Discovery, Presented by Sandra MM., leadXpro AG
C064: Envisia: Advancing Antibody Discovery with Function-Focused Profiling at the Single-Cell Level, Presented by Simon M., Lightcast Discovery Ltd.
C065: From iPSCs to Immune Cells: High-Throughput Production and Single-Cell Functional Analysis with Droplet Microfluidics, Presented by Natacha C., LiveDrop Bio
C066: Is Spray-Drying Really That Harsh on Proteins?, Presented by Jesús ECP., Lund University
C067: LxbioAb End-to-End Antibody Discovery Platform: A Case Study, Presented by Natalia S., Lxbio
C068: Advancing the Discovery and Development of Biologics and Next-Generation Immunotherapies through Innovative Expression and Screening Techniques, Presented by Alicia RM., MaxCyte
C069: Multi-Parametric Lead Prioritization from Terminal Single-Cell B Cell Repertoires, Presented by Maddi LB., MiLaboratories
C070: Bulk Humanization of Murine and Camelid Antibodies Accelerates Biologics Discovery with Minimal Variants, Presented by Thijs D., Mosaic Biosciences, Inc.
C071: Understanding and Engineering PETase Across Temperature, Product Inhibition and PET Crystallinity, Presented by Nitish JS., Nanyang Technological University
C072: Affinity Based Purification of Hyaluronidase by Using NaviCapture Ligands, Presented by Hanna B., Navigo Proteins GmbH
C073: Beyond Binding: Human Immune Cell Assays for Assessing Antibody Fc Function, Presented by Silvia R., Nexus BioQuest
C074: FIDA Profiling for Peptide and Miniprotein Screening in Pharmaceutical Development, Presented by Christin L., Novo Nordisk A/S
C075: NovoFy - Designing the Inaccessible: Generative Minibinders for Intracellular Targets, Presented by Fernando G., NovoFy, Inc.
C076: From DNA to Active, Monomeric β1AR Receptor in <72 Hours Using Cell-Free Synthesis, Presented by Mathias BT., Nuclera
C077: Cell-Free–Produced Antibodies Match CHO for Binding Assessment, Presented by Juhi M., Nuclera
C078: Development of OmniUltra™: A Transgenic Chicken System for the Generation of Ultralong CDRH3 Antibodies, Mini-Proteins, and Structured Peptides, Presented by Chris B., OmniAb
C079: Optimizing the Right Candidates: Live-Cell Validation of Impermeable Peptides and Novel Modality Candidates Prior to MedChem, Presented by Ani N., Portal Biotech Ltd.
C080: High Efficiency Protein A Affinity Columns for the LC-MS and 2D LC-MS Analysis of mAb and bsAb, Presented by Géry V., Quality Assistance
C081: Lead Discovery and Functionalization of Single-Domain Antibodies for Detection and Imaging of G Protein-Coupled Receptors, Presented by Stephanie A., QVQ Holding BV
C082: Predicting the Dynamic Viscosity of High-Concentration Protein Solutions with Martini 3, Presented by Tobias P., Ruhr University Bochum
C083: A Computational Design Strategy for Biologics Engineering, Presented by Oliver HC., Sanofi
C084: Total Holographic Characterization Reveals Protein Aggregates Hiding in Silicone Oil, Presented by Laura P., Spheryx, Inc.
C085: Targeted LNPs Made Simple: An Affinity-Based Platform for Efficient CAR-M Therapeutics, Presented by Rosanne V., Strike Pharma AB
C086: Generation of High-Affinity Monoclonal Antibodies Targeting Tumor-Associated Carbohydrate Antigens (TACAs): Two Successful Case Studies, Presented by Stephan G., Tacalyx GmbH
C087: Detection of Bacterial Potato Pathogens with Antibody Phage Display-Selected Antibodies, Presented by Charlotte K., Technische Universität Braunschweig
C088: Discovery of TCRm-Antibodies Targeting PRAME[425-433] from a Chicken scFv Library, Presented by Elena H., Technische Universität Darmstadt
C089: From Monoclonal to Bispecific: Leveraging Chicken Antibody Repertoires and Human Common Light Chain Strategy for Next-Generation Immune Cell Engagers, Presented by Paul P., Technische Universität Darmstadt
C090: Bispecific GM-CSF Mimetics Resistant to Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patient-Derived Anti-GM-CSF Autoantibody Responses, Presented by Hue T., Technische Universität Darmstadt
C091: Gibco™ ExpiCHO™ K1 PRO Prototype Expression System: High-Yield, Fast, and Scalable Transient Protein Expression in CHO-K1 Cells, Presented by Chao Yan L., Thermo Fisher Scientific
C092: Automating Expi293™ PRO and ExpiCHO™ K1 PRO Expression Systems for mAb and Fc Fusion Protein Production, Presented by Nan Y., Thermo Fisher Scientific
C093: High-Throughput Protein Stability Screens with Aunty, Presented by Andre M., Unchained Labs
C094: From Polysorbate Degradation to Protein Quality: A Complementary Analytical Approach, Presented by Fatos S., Universität Basel
C095: Evaluating Large Language Model Influence on Agentic Behavior in the Context of Minibinder Design, Presented by Johanna M., Universität Leipzig
C096: Novel TNFR2 Nb-Fusion Proteins with ADCC-Inducing Capacity to Attenuate GvHD and Enhance GvL Activity, Presented by Sofia HG., University Hospital Würzburg
C097: Novel Naturally Occurring Antibodies for Immunotherapy in Neuroblastoma, Presented by Celine P., University Medical Center Hamburg-Eppendorf (UKE)
C098: CER-21: A Next-Generation sdAb-Based Immune Checkpoint Inhibitor for Canine Cancer, Presented by Remy B., University of Bern
C099: “If You Like It Then You Shoulda Put a Macrocyclic Peptide on It”: Rational and Structure-Guided Drug Design of Macrocyclic Peptides to Modulate C1, Presented by Jenn-Yeu S., University of Bristol
C100: Generation of Immune-Derived Naja PLA2-Neutralising Recombinant Antibodies by Phage Display, Presented by Rhys D., University of Cambridge
C101: ML Design of Nanobodies Enables Affinity Maturation and α2/α3 Selectivity Switching in GABA[A] Receptors, Presented by Nergis I., University of Cambridge
C102: Generation of Recombinant Neutralising Antibodies Against Snake Venom Metalloproteases, Presented by Jonathan R., University of Cambridge
C103: Biophysical Profiling of Biosurfactants for Protein and Peptide Stability in Biologic Formulations, Presented by Zartashia S., University of Huddersfield
C104: Engineering Trop2-Targeted Degrader-Antibody Conjugates for Triple-Negative Breast Cancer: A Comparative Oncology Approach, Presented by Rafaela M., University of Lisbon
C105: Dual-Payload ADC Development for Canine Lymphoma: Combining Payloads with Distinct Mechanisms of Action in a Comparative Model of Human Non-Hodgkin Lymphoma, Presented by Rita P., University of Lisbon
C106: Using Peptide Microarrays as Low Demand, High Throughput Formulation Screens, Presented by Arush A., University of Manchester
C107: 'Sequence Manipulation of DNA to Enhance Biopharmaceutical Production, Presented by Ryan H., University of Sheffield
C108: Understanding the Stabilization Effect of Excipients on Monoclonal Antibodies Through Integrated Experimental and Molecular Dynamics Studies, Presented by Kaho K., University of Strathclyde
C109: Improving Genotyped Functional Screening: A Universal Closed-Tube PCR for Illumina Library Generation Reduces Phantom Sequences in Multiplexed Sequencing, Presented by Urpo L., University of Turku
C110: Optimization of Liquid Chromatography – Mass Spectrometry Analysis for Stability Study and Quantification of Protein Oligonucleotide Conjugates, Presented by Magali G., Vect-Horus
C111: Distinct Geometries, Comparable Interfaces: Binding Modes and Thermodynamic Implications in Conventional and Single Domain Antibodies, Presented by Antoine H., Vect-Horus
C112: Beyond the Freezer: Unlocking Stable and Scalable Viral Biologics, Presented by Clarinda S. & Elsa A., ViSync
C113: AI-MPRO: Tackling Challenging Targets with De Novo Miniproteins, Presented by Irena A., VRG Therapeutics
C114: Determining HMWS in Cell Culture Using a Simplified 2D Protein A Affinity Size Exclusion Chromatography Method, Presented by Steven C., Waters Corporation
C115: Characterization of GLP-1 Oligomers and Higher-Order Structures Following Recent Regulatory Changes, Presented by Felix G., Waters Corporation
C116: Breaking the Barriers to Antibody-Oligonucleotide Conjugate (AOC) Site Conjugation Determination and Oligo-Peptide Conjugates by LC-MS, Presented by Ben W., Waters Corporation
C117: Structure-Guided Design and Biophysical Evaluation of Peptides Targeting the CD47–SIRPα Interaction, Presented by Paulina F., Wroclaw Medical University
C119: A Fully Regenerable SPR Platform for High-Throughput Mapping of Protein-Protein Interfaces Without Purification of Ligand Variants, Presented by John K., Zag Bio
ADDITIONAL VIRTUAL POSTERS
V1: Development of Antibody-Antimicrobial Conjugates (AAC) to Fight Infectious Diseases, Presented by Martina C., Università degli Studi di Siena